Millions of Medicare Part D enrollees who depend on drugs like Ozempic, cancer treatments, and medications for chronic conditions will pay sharply less starting January 1, 2027, after the Centers for Medicare and Medicaid Services finalized negotiated prices on 15 high-cost drugs. The agency projects the second round of its Drug Price Negotiation Program will cut costs by roughly 44 percent across the selected medications, translating to about $12 billion in savings for Medicare and its beneficiaries.
Lower prices on 15 drugs shift the cost equation for Part D enrollees
The 15 drugs in this second negotiation cycle treat some of the most common and expensive conditions among older Americans, including diabetes, cancer, and other chronic diseases. All 15 manufacturers reached agreement with CMS on maximum fair prices, meaning none walked away from the process or triggered the steep excise tax penalties that the Inflation Reduction Act imposed as an alternative. That unanimous participation signals that drugmakers, however reluctantly, have accepted the new pricing framework for now.
Among the highest-profile drugs on the list is semaglutide, marketed as Ozempic and Rybelsus for diabetes and as Wegovy for weight management. CMS published per-drug explanation files, including one covering the semaglutide products, detailing how the agency arrived at each maximum fair price. The 44 percent average reduction represents a net figure after accounting for existing rebates and discounts, so the sticker-price drop alone does not tell the full story. Still, the practical result is that out-of-pocket spending for beneficiaries filling these prescriptions should fall once the prices take effect.
CMS has emphasized that the negotiated prices are designed to reflect clinical benefit, unmet medical need, and comparative effectiveness, rather than simply forcing across-the-board cuts. For patients, however, the most visible change will be at the pharmacy counter. Lower list prices flow through to lower coinsurance and copayments, especially for beneficiaries who use multiple high-cost drugs and are more likely to hit the Part D catastrophic threshold under current pricing.
A reasonable expectation is that lower cost sharing will improve medication adherence. Research across multiple therapeutic areas has consistently shown that when patients pay less at the pharmacy counter, they are more likely to fill and refill prescriptions on schedule. Part D claims data from 2027 and 2028 could provide the first direct evidence of whether the negotiated prices produce a measurable uptick in adherence rates for these 15 drugs, a signal that analysts and policymakers will watch closely.
CMS savings projections and Novo Nordisk’s pricing risks
The $12 billion savings estimate comes directly from CMS and covers the combined effect of all 15 negotiated maximum fair prices against what Medicare would otherwise have paid. In outlining these projected savings for beneficiaries and taxpayers, the agency described how lower prices on drugs treating cancer and chronic diseases would reduce both premiums and out-of-pocket costs for enrollees. The 44 percent average reduction is the headline metric CMS has promoted in its announcement that it is delivering savings on this group of medications.
Detailed guidance documents governing the second cycle, including definitions of “maximum fair price,” data submission requirements, and the process milestones manufacturers must follow, are housed in the agency’s official negotiation guidance. These materials spell out how CMS weighs factors such as R&D costs, federal support for early-stage science, and prices in other health systems when formulating its opening offers and counterproposals.
For Novo Nordisk, the Danish company behind semaglutide, the pricing pressure is a disclosed financial risk. While the company has enjoyed surging revenue from Ozempic and related products in commercial markets, Medicare’s new authority to negotiate prices introduces uncertainty around future U.S. margins. Because the negotiated prices apply to a defined Medicare population and start date, Novo Nordisk and its peers must balance lower unit revenue in Part D against potential volume gains if more patients initiate or remain on therapy once prices fall.
That trade-off is especially salient for chronic conditions like diabetes, where long-term adherence can prevent costly complications such as heart attacks, strokes, and kidney failure. If negotiated prices lead to better glycemic control for Medicare beneficiaries, the program could realize secondary savings in reduced hospitalizations and fewer acute episodes, above and beyond the direct $12 billion in projected drug-spending reductions. Those downstream effects will take years to quantify, but they form a central part of the policy rationale for the negotiation program.
Drugmakers, meanwhile, are likely to keep testing the legal and political boundaries of the Inflation Reduction Act’s pricing provisions even as they comply with the current rounds of negotiation. With the second cycle now finalized and a third wave of drugs already identified for future talks, CMS is signaling that negotiated prices will become a recurring feature of the Part D landscape. For Medicare enrollees who rely on expensive therapies, the 2027 start date for these 15 drugs marks the beginning of a new era in which federal bargaining power, rather than solely market dynamics, plays a decisive role in what they pay at the pharmacy.
